Fundamentals and stats

An in-depth look to Marker Therapeutics, Inc. operating, investing, and financing activities

GX1 free cash flow for Q2 25 is -1.59 M EUR. For 2024, GX1 free cash flow was -10.54 M EUR and operating cash flow was -10.54 M EUR.

Q3 '17

Q4 '17

Q1 '18

Q2 '18

Q3 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

Cash from operating activities

Cash from investing activities

Cash from financing activities

Currency: EUR